Micro<scp>RNA</scp>‐802 plays a tumour suppressive role in tongue squamous cell carcinoma through directly targeting <scp>MAP</scp>2K4

Wu, Xiaozhen; Gong, Zuode; Sun, Lingyun; Ma, Long; Wang, Qibao

doi:10.1111/cpr.12336

Cited by 35 publications

(39 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In gastric cancer miR-802 was down regulated and found to act as a tumor suppressor by directly targeting RAB23 [ 39 ]. Likewise, in tongue and prostate cancer, miR-802 has been described with a tumor suppressing function [ 40 , 41 ]. In prostate cancer miR-802 was found to suppress epithelial-mesenchymal transition (EMT) [ 40 ].…”

Section: Discussionmentioning

confidence: 99%

Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer

et al. 2018

View full text Add to dashboard Cite

BackgroundOvarian cancer is the leading cause of death by gynecologic cancers in the Western world. The aim of the study was to identify microRNAs (miRNAs) associated with prognosis and/or resistance to chemotherapy among patients with epithelial ovarian cancer.MethodsUsing information from the Pelvic Mass Study we identified a cohort of women with epithelial ovarian cancer. Tumor tissues were then collected and analyzed by global miRNA microarrays. MiRNA profiling was then linked to survival and time to progression using Cox proportional-hazards regression models. Logistic regression models were used for the analysis of resistance to chemotherapy. Our results were validated using external datasets retrieved from the NCBI Gene Expression Omnibus database.ResultsA total of 197 patients with epithelial ovarian cancer were included for miRNA microarray analysis. In multivariate analyses we identified a number of miRNAs significantly correlated with overall survival (miR-1183 (HR: 1.42, 95% CI:1.17–1.74, p = 0.0005), miR-126-3p (HR: 1.38, 95% CI:1.11–1.71, p = 0.0036), time to progression (miR-139-3p (HR: 1.48, 95% CI: 1.13–1.94, p = 0.0047), miR-802 (HR: 0.48, 95% CI: 0.29–0.78, p = 0.0035)), progression free survival (miR-23a-5p (HR:1.32, 95% CI:1.09–1.61, p = 0.004), miR-23a-3p (HR:1.70, 95% CI:1.15–2.51, p = 0.0074), miR-802 (HR: 0.48, 95% CI: 0.29–0.80, p = 0.0048)), and resistance to chemotherapy (miR-1234 (HR: 0.26, 95% CI: 0.11–0.64, p = 0.003)). A few miRNAs identified in our training cohort, were validated in external cohorts with similar results.ConclusionEight miRNAs were identified as significant predictors of overall survival, progression free survival, time to progression, and chemotherapy resistance. A number of these miRNAs were significantly validated using external datasets. Inter-platform and inter-laboratory variations may have influence on the ability to compare and reproduce miRNA results. The use of miRNAs as potential markers of relapse and survival in ovarian cancer warrants further investigation.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…It was determined that certain miRNAs participated in cellular behaviors, such as cell-cycle regulation, inflammation, stress response, migration, invasion, differentiation and apoptosis [6]. Dysregulation of miRNAs is commonly observed in diverse tumors, including TSCC, and closely related to cancer progression, functioning as either tumor oncogenes or suppressors [7,8]. MiR-26a and miR-26b make up the miR-26 family [9].…”

Section: Introductionmentioning

confidence: 99%

MiR-26a/miR-26b represses tongue squamous cell carcinoma progression by targeting PAK1

et al. 2020

View full text Add to dashboard Cite

Background: Tongue squamous cell carcinoma (TSCC) is the most common oral malignancy. Previous studies found that microRNA (miR)-26a and miR-26b were downregulated in TSCC tissues. The current study was designed to explore the effects of miR-26a/miR-26b on TSCC progression and the potential mechanism. Methods: Expression of miR-26a, miR-26b and p21 Activated Kinase 1 (PAK1) in TSCC tissues and cell lines was detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Flow cytometry analysis was performed to examine cell cycle and apoptosis. Transwell assay was conducted to evaluate the migrated and invasive abilities of SCC4 and Cal27 cells. In addition, western blot assay was employed to analyze the protein level. Glucose assay kit and lactate assay kit were utilized to analyze glycolysis. Dual-luciferase reporter and RNA immunoprecipitation (RIP) assays were applied to explore the relationship between miR-26a/miR-26b and PAK1. Xenograft tumor model was constructed to explore the role of miR-26a/miR-26b in vivo. Results: Both miR-26a and miR-26b were underexpressed, while PAK1 was highly enriched in TSCC. Overexpression of miR-26a and miR-26b inhibited TSCC cell cycle, migration invasion and glycolysis, while promoted cell apoptosis. Both miR-26a and miR-26b directly targeted and negatively regulated PAK1 expression. Introduction of PAK1 partially reversed miR-26a/miR-26b upregulation-mediated cellular behaviors in TSCC cells. Gain of miR-26a/miR-26b blocked TSCC tumor growth in vivo. Conclusion: MiR-26a/miR-26b repressed TSCC progression via targeting PAK1 in vitro and in vivo, which enriched our understanding about TSCC development and provided new insights into the its treatment.

show abstract

“…However, due to the side effects of drugs and the problem of distant metastasis, the prognosis is poor [6]. In recent years, gene targeting therapy, which can effectively reduce the toxicity and side effects of drugs, has shown its unique advantages in the clinical treatment of many diseases and has received more and more attention [7,8].…”

Section: Introductionmentioning

confidence: 99%

Association of SP1 rs1353058818 and STAT3 rs1053004 gene polymorphisms with human tongue squamous cell carcinoma

Lai

Meng³

et al. 2019

Bioscience Reports

View full text Add to dashboard Cite

Objective: To study the association between SP1 rs1353058818 and STAT3 rs1053004 gene polymorphisms and risk of human tongue squamous cell carcinoma (TSCC). Methods: Sanger sequencing was used to determine the genotypes of SP1 rs1353058818 and STAT3 rs1053004 loci in 240 TSCC patients and 240 controls. Levels of hsa-miR-149-5p and hsa-miR-21-5p and expression levels of SP1 and STAT3 proteins in tumor tissues and adjacent normal tissues of TSCC patients were ascertained. Results: Carrying the SP1 rs1353058818 locus deletion allele was a high risk factor for TSCC (OR = 2.997, 95% CI: 1.389–6.466, P = 0.003). The STAT3 rs1053004 locus A allele was a protective factor for TSCC (OR = 0.604, 95% CI: 0.460-0.793, P < 0.001). There was a negative correlation between SP1 mRNA and hsa-miR-149-5p in tumor and adjacent normal tissues (r = −0.81, −0.77). The expression of SP1 protein in tumor tissues of the SP1 rs1353058818 locus DD genotype was significantly higher than in tissues of the ID type, and in tissues of type II it was the lowest. STAT3 mRNA was positively correlated with hsa-miR-21-5p in tumor and adjacent normal tissues (r = 0.75, 0.78). The expression level of STAT3 protein in tumor tissues of patients with STAT3 rs1053004 locus GG genotype was significantly higher than in patients with type GA, and it was the lowest in patients with type AA. Conclusion: Polymorphisms in the SP1 rs1353058818 and STAT3 rs1053004 loci are associated with the risk of human TSCC.

show abstract

MicroRNA‐802 plays a tumour suppressive role in tongue squamous cell carcinoma through directly targeting MAP2K4

Abstract: Our data revealed that miR-802 played as a tumour suppressor gene and might act as a therapeutic target in TSCC patients.

Cited by 35 publications

References 38 publications

Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer

Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer

MiR-26a/miR-26b represses tongue squamous cell carcinoma progression by targeting PAK1

Association of SP1 rs1353058818 and STAT3 rs1053004 gene polymorphisms with human tongue squamous cell carcinoma

Contact Info

Product

Resources

About